Sign up


Match Document Document Title
8431535 Methods for treating local tracheal, bronchial or alveolar bleeding or hemoptysis  
The present invention provides methods for the local treatment of tracheal, bronchial or alveolar bleeding or hemoptysis and/or reducing unwanted effects associated with systemic administration of...
8420079 Recombinantly modified plasmin  
Polynucleotides and polypeptides relating to a recombinantly-modified plasmin(ogen) molecule are provided. The plasmin(ogen) molecule has a single kringle domain N-terminal to the activation site...
8415458 Modified vitamin K-dependent polypeptides  
The invention provides vitamin K-dependent polypeptides with enhanced membrane binding affinity. These polypeptides can be used to modulate clot formation in mammals. Methods of modulating clot...
8415457 Modified vitamin K-dependent polypeptides  
The invention provides vitamin K-dependent polypeptides with enhanced membrane binding affinity. These polypeptides can be used to modulate clot formation in mammals. Methods of modulating clot...
8410048 Method for producing insulin analogs having a dibasic B chain terminus  
The invention relates to a method for producing a type of insulin by genetically engineering a precursor thereof and converting said precursor to the respective insulin in an enzyme-catalyzed...
8389261 Method of isolation and purification of trypsin from pronase protease and use thereof  
The present invention provides methods of isolation and purification of Streptomyces griseus trypsin (SGT) from PRONASE protease mixture in a single affinity chromatography step and uses of the...
8383105 Pharmacological vitreolysis  
A method of treating or preventing a disorder, or a complication of a disorder, of an eye of a subject comprising contacting a vitreous and/or aqueous humor with a composition comprising a...
8383104 Thrombin-free biological adhesive and use thereof as a medicament  
The invention relates to a thrombin-free, fibrinogen-based biological adhesive for therapeutic use, which comprises factor VIIa and a source of calcium ions. The invention also relates to the use...
8383388 Modified coagulation factor IX polypeptides and use thereof for treatment  
Provided are modified factor IX (FIX) polypeptides and methods of generating modified FIX polypeptides. Also provided are pharmaceutical compositions, including compositions formulation for oral...
8377420 Injectable void filler for soft tissue augmentation  
The present invention teaches a micro-porous injectable, soft elastic, fully resorbable fibrin-based composition for use as a soft tissue lumen and void filler. The composition of the present...
8377864 Fibrin gel for controlled release of PDGF and uses thereof  
The present invention relates, in general, to fibrin sealants, which contain platelet derived growth factor (PDGF) for controlled release in situ for therapeutic applications, including...
8357365 Granulysin peptides and methods of use thereof  
Granulysin peptides are small antimicrobial agents with potent activity. A pharmaceutical composition comprising granulysin peptides as an active agent is administered therapeutically to a patient...
8337836 Methods for the treatment and prevention of diseases of biological conduits  
Methods are described for dilating biological conduits by removing elastin and remodeling collagens in the wall of the conduit. Methods include the use of agents that increase the release of...
8329168 Compositions and methods for modulating hemostasis  
Novel thrombin/prothrombin protease/zymogen variants which have anticoagulation activity and methods of use thereof are disclosed.
8318904 Liquid, aqueous pharmaceutical compositions of factor VII polypeptides  
The present invention is directed to liquid, aqueous pharmaceutical compositions stabilized against chemical and/or physical degradation containing Factor VII polypeptides, and methods for...
8313744 Composition for the prevention and treatment of absence seizures comprising PKC agonist as an effective ingredient  
The present invention relates to a composition comprising PKC agonist as an active ingredient. More precisely, the present inventors confirmed that absence seizure specific SWD was reduced by...
8293281 Analgesic and anti-inflammatory composition  
The present invention discloses a composition that contains (1) an effective amount of an analgesically and/or anti-inflammatory active fraction separated from a mixture of plasma and/or serum, and...
8293231 Methods and compositions for treating ischemia  
A method for treating ischemia that would benefit from angiogenesis is disclosed. The method comprises administering to a subject in need thereof a composition comprising: a) a fragment of human...
8293213 Method and apparatus for thrombus removal using magnetic particles  
A method and system for affecting a thrombus after ischemic stroke. The method may include injecting a plurality of magnetic particles into a bloodstream and moving or distorting a thrombus formed...
8268783 Antidotes for factor Xa inhibitors and methods of using the same  
The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor X and factor Xa protein derivatives that bind to the factor Xa inhibitors thereby...
8257700 Proteomic analysis of active multiple sclerosis lesions  
The invention provides methods for treating demyelinating inflammatory diseases by administering to the subject an effective amount of an agent that provides activated protein C activity, where the...
8252340 Extract for treating thrombotic diseases  
An extract for preventing or treating thrombotic disease, particularly, an extract of leech and/or earthworm with molecular weight of not more than 5800 Dalton, and processes for preparation,...
8252302 Methods and compositions to treat hemorrhagic conditions of the brain  
The described invention provides a nonhuman animal model system for hemorrhagic brain conditions, methods for evaluating a substance for treating the hemorrhagic brain condition in a mammal,...
8236355 COX-2 inhibitor  
The present invention relates to an agent having COX-2 inhibition activity. In particular the present invention relates to a COX-2 inhibitor separated from a mixture of denatured plasma and at...
8231870 Pharmaceutical preparation for treating benign prostatic hyperplasia  
The present invention relates to the use of at least one protease for the manufacture of a medicament for the treatment and/or prevention of benign prostate hypertrophy/hyperplasia, wherein the...
8231869 Recombinant plasmin for opthalmic indications  
Methods of using polynucleotides and polypeptides relating to a recombinantly-modified plasmin(ogen) molecule are provided, including methods related to vitrectomy or vitreolysis. The plasmin(ogen)...
8226942 PDGF fusion proteins incorporated into fibrin foams  
Compositions for wound healing, use of the compositions, and kits and methods of using thereof are described herein. In a preferred aspect, the compositions are suitable for use in a method for...
8216568 Combination therapy with IgA1 proteases  
The present invention discloses the use of bacterial IgA1 proteases to treat IgA1 deposition in tissue and organs. Bacterial IgA1 proteases specifically cleave IgA1 molecules and thus provide a...
8212003 Bifunctional fusion protein with thrombolytic and anticoagulant activities and uses thereof  
This application relates to a fusion protein, which is composed of a thrombolytic protein, an anticoagulant protein, and a linker peptide. In particular, the fusion protein is composed of an...
8211428 Protease screening methods and proteases identified thereby  
Methods for identifying modified proteases with modified substrate specificity or other properties are provided. The methods screen candidate and modified proteases by contacting them with a...
8206967 Method for production of recombinant human thrombin  
The present invention relates to compositions and methods for producing recombinant human thrombin using recombinant ecarin.
8187592 C1-inhibitor prevents non-specific plasminogen activation by a prourokinase mutant without impeding fibrin-specific fibrinolysis  
A mutant prourokinase plasminogen activator (M5) was developed to make prouPA less subject to spontaneous activation during fibrinolysis. C1-inhibitor complexes with tcM5. The effect of...
8182808 Recombinantly modified plasmin  
Polynucleotides and polypeptides relating to a recombinantly modified plasmin(ogen) molecule are provided. The plasmin(ogen) molecule has a single kringle domain N-terminal to the activation site...
8163734 Use of a mast cell activation or degranulation blocking agent in the manufacture of a medicament for the treatment of a patient subjected to thrombolyses  
The invention concerns the use of a mast cell activation- or degranulation-blocking agent in the manufacture of a medicament for preventing and treating cerebral complications caused by...
8153590 Antidotes for factor Xa inhibitors and methods of using the same  
The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially...
8138157 Antibiotic formulation and method of treatment  
A formulation comprised of particles which may be in groups and are comprised of a biocompatible polymer and an antimicrobial drug for controlled release of the drug is disclosed. The particles may...
8137701 Method of producing a dry earthworm powder  
Provided is a method of producing a dry earthworm powder without deterioration in useful pharmacological action, by removing dirt on the skin of earthworms while allowing the earthworms to excrete...
8137666 Nattokinase for degrading and reducing amyloid fibrils—associated with alzheimer's disease, prion diseases and other amyloidoses  
A method of dissolving or disrupting pre-formed or pre-deposited amyloid fibrils and/or inhibiting amyloid formation, deposition, accumulation, or persistence in Alzheimer's disease, prion diseases...
8124737 Stabilized preparations of serine endopeptidases, their preparation and use  
The invention relates to stabilized preparations of serine endopeptidases which are suitable for use as a test reagent in a diagnostic procedure or for a therapeutic use. As a result of the...
8124075 Enhanced biological autologous tissue adhesive composition and methods of preparation and use  
The invention includes a composition useful for preparing a tissue sealant for use on a patient, comprising: autologous fibrinogen, an activating agent and at least one supplement. The invention...
8088372 Thrombin mutant  
A thrombin mutant in which at least serine at position 205 among amino acids in the active center of the thrombin B chain has been replaced with another amino acid, and further at least one of the...
8071091 Non-neurotoxic plasminogen activating factors for treating stroke  
The invention pertains to the use and production of non-neurotoxic plasminogen activating factors e.g. of Desmodus rotundus (DSPA) for the therapeutic treatment of stroke in humans in order to...
8071090 Stabilized thrombin compositions  
Stabilized thrombin compositions, processes for preparing them, and kits comprising them are disclosed. The compositions comprise thrombin, a bacteriostatically effective amount of benzyl alcohol...
8067187 Cross-β structure binding compounds  
The invention relates to the field of biochemistry, biophysical chemistry, molecular biology, structural biology and medicine. More in particular, the invention relates to cross-β structure ...
8062635 Bispecific antibody substituting for functional proteins  
The present inventors succeeded in constructing bispecific antibodies, which bind to both the blood coagulation factor IX/activated blood coagulation factor IX and blood coagulation factor X, and...
8043629 Bioabsorbable synthetic nonwoven fabric holding thrombin  
A safe and effective hemostatic is provided. The invention relates to a bioabsorbable synthetic nonwoven fabric holding thrombin as an effective ingredient and a hemostatic comprising said...
8007774 Matrix composed of a naturally-occurring protein backbone cross linked by a synthetic polymer and methods of generating and using same  
The present invention relates to biodegradable scaffolds composed of a naturally-occurring protein backbone cross-linked by a synthetic polymer. Specifically, the present invention provides...
8003096 Means and methods for the recruitment and identification of stem cells  
Described are methods of modulating stem/progenitor cell recruitment involving molecules that agonize the formation of plasmin stimulating the recruitment of stem/progenitor cells, including...
7993899 Method for the purification of chymosin  
We describe a method for purifying chymosin comprising providing an aqueous liquid sample containing chymosin and a separation medium comprising a base matrix and a plurality of firmly attached...
7976837 Method of preventing and treating brain infarction  
The present invention is intended to clarify the relationship between PAR-2 and cerebral infarction and thereby provide an efficient method of preventing and treating cerebral infarction, as well...